Quantification of fibrin degradation products in glioma and meningioma patients

Article type: Research Article

Authors: Can, Ozge^{a; d; *} | Erdemgil, Yigit^{a; d} | Yildirim, Zeynep Zulfiye^{a; d} | Ozduman, Koray^{b; d} | Pamir, M. Necmettin^{b; d} | Sav, Aydın^{c; d} | Ozpinar, Aysel^{a; d}

Affiliations: [a] Department of Medical Biochemistry, Acibadem Univeristy, Istanbul, Turkey | [b] Department of Neurosurgery, Acibadem Univeristy, Istanbul, Turkey | [c] Department of Pathology, School of Medicine, Acibadem University, Istanbul, Turkey | [d] Acibadem University Neuroscience Center – Brain Tumor Research Group, Acibadem University, Istanbul, Turkey

Correspondence: [*] Corresponding author: Ozge Can, Acıbadem University Kerem Aydinlar Campus, Icerenkoy Mahallesi, Kayısdagi Caddesi, No: 32, Atasehir, Istanbul, Turkey. Tel.: +90 216 5004061; Fax: +90 216 5765076; E-mail: ozge.can@acibadem.edu.tr.

Abstract: Background:DR-70 is an immunoassay for fibrin and FDP in plasma and it has been shown useful in detection of over 14 different cancers. This study investigated the validity of the DR-70 test in gliomas as well as meningiomas. Methods:77 brain tumor patients as well as 40 healthy individuals were prospectively included in the study and investigated using DR-70 kit. The glioma cohort of 33 patients consisted of 1, 11, 6 and 15 WHO grade 1, 2, 3 and 4 gliomas, respectively. The meningioma cohort of 44 patients contained 38, 5 and 1 WHO grade 1, 2 and 3 tumors. Results:Test results were significantly higher than control values for both gliomas and meningiomas. The most balanced sensitivity and specificity values were obtained at cut-off level of 0.5 µg/ml FDP for both gliomas and meningiomas. Above this cutoff level the relative-risk for having a glioma was 5.1 times higher compared to controls with sensitivity and specificity of 76% and 85%, respectively. The relative-risk for meningioma was 5.8 with a sensitivity and specificity of 87% and 85%, respectively. Conclusion:FDP testing, which is a nonspecific cancer screening tool, is sensitive to the two most common primary brain malignancies, gliomas and meningiomas.

Keywords: Meningioma, glioma, fibrin degradation products, DR-70

DOI: 10.3233/CBM-140400

Journal: Cancer Biomarkers, vol. 14, no. 4, pp. 253-258, 2014